Beclobrate is a fibric acid derivative used primarily as a lipid-lowering agent. It effectively reduces triglyceride levels in the blood and can modestly lower LDL cholesterol while increasing HDL cholesterol. It is prescribed to manage hyperlipidemias, particularly type IIb, III, IV, and V, characterized by elevated lipids, to help prevent cardiovascular diseases such as atherosclerosis, heart attacks, and strokes. Beclobrate works by activating peroxisome proliferator-activated receptor alpha (PPARα), which promotes fatty acid β-oxidation in the liver, enhances lipoprotein lipase activity to increase triglyceride clearance, and reduces apolipoprotein C-III synthesis. It is administered orally and is typically part of a comprehensive treatment plan that includes dietary modifications and exercise. Regular monitoring of lipid levels and liver function is recommended to evaluate efficacy and monitor for potential side effects.